Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03850366 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jan 1, 2027 to Jan 1, 2028v7
  2. Primary completion date: Jan 1, 2025 to Jan 1, 2027
    • Study completion date: Jan 1, 2026 to Jan 1, 2027
    v6
  3. Study completion date: Jan 1, 2025 to Jan 1, 2026v5
  4. Primary and study completion dates: Jan 1, 2023 to Jan 1, 2025v4
  5. 2 versions Re-verified since Nov 3, 2020, no change to tracked fieldsv2-v3
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patients with hematologic malignancies who need allogeneic stem cell transplant but do not have a suitable matched related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and bortezomib
Trial Details
NCT Number NCT03850366
Lead Sponsor Henry Ford Health System
Conditions
(from sponsor)		 Hematological Malignancy
Related terms Hematologic Neoplasms
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov